Author

Albert Gris‐Oliver

Consorci Institut D'Investigacions Biomediques August Pi I SunyerORCID 0000-0003-1802-9541Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Organism:human· 1 Organism:mouse· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Agavni MesropianiD· 2 shared Josep Maria LlovetiD· 2 shared Roser PinyoliD· 2 shared Ailith EwingiD· 1 shared Alexis I. CocozakiiD· 1 shared Alison M. MeynertiD· 1 shared Amaya López-PascualiD· 1 shared Ana Hernández de SandeiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Agavni MesropianORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacology & ToxicologyCell Reports MedicinePeer-reviewedMar 31, 2026

Histone methyl-transferase G9a inhibition boosts the efficacy of immune checkpoint inhibitors in experimental hepatocellular carcinoma

Elena Adán-Villaescusa, Borja Castelló-Uribe, Iker Uriarte…·Maite G Fernandez-Barrena

This study shows that inhibiting G9a enhances the effectiveness of immune checkpoint inhibitors in hepatocellular carcinoma by improving tumor immunogenicity and T cell infiltration.

3 citationstop 2%

mousebulk RNA-seq

𝕏 PostBluesky

Cancer BiologyNature GeneticsPeer-reviewedFeb 1, 2026

Mutational scanning reveals oncogenic CTNNB1 mutations have diverse effects on signalling and clinical traits

Anagha Krishna, Alison M. Meynert, Karamjit Singh Dolt…·Derya Deniz Ozdemir

The paper quantifies signalling effects of CTNNB1 mutations across cancer types and finds weakly activating mutations correlate with worse prognosis in hepatocellular carcinoma.

16 citationstop 1%

humanwhole-genome sequencing

𝕏 PostBluesky